ReportWire

Tag: Medical research

  • New play looking at friendship between AIDS activist Larry Kramer and Anthony Fauci in the works

    NEW YORK — A new play exploring the complex relationship between playwright and AIDS activist Larry Kramer and Dr. Anthony Fauci, the longtime top U.S. infectious disease expert, will make its premiere early next year in New York under the direction of Tony Award-winner Daniel Fish.

    “Kramer/Fauci” will star Tony-winner Will Brill from “Stereophonic” and Thomas Jay Ryan, who starred in the film “Henry Fool.” It will play The Jack H. Skirball Center for the Performing Arts between Feb. 11-21, The AP has learned.

    Fish, whose 2019 production of Rodgers and Hammerstein’s “Oklahoma!” won the Tony Award for best musical revival, is using the transcript of a 1993 C-Span face-off between the two men as the text of the play, which included call-ins from across the country.

    “I’m looking at a particular moment in time, at a particular exchange that has resonances into their relationship, has resonances into the politics and culture of the time, and seeing what happens when we do that now. That’s really where I’m coming from,” said Fish.

    Kramer and Fauci went from adversaries to friends as they confronted the AIDS crisis from different sides in the 1980s and ’90s. Kramer, who wrote “The Normal Heart” and founded the AIDS Coalition to Unleash Power, or ACT UP, demanded the government do more and faster for those with symptoms.

    Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases, insisted on a pragmatic approach. He would became a lightning rod again as leader of the national response to the coronavirus pandemic in 2020.

    The exchange in 1993 was heated and illuminating, with Kramer acknowledging their complex relationship: “He is a man, an ordinary man, who is being asked to play God,” Kramer said at the time. “And he is being punished because he cannot be God. And that is a terrible position to be in.”

    After Kramer’s death in 2020, Fish stumbled across the C-Span exchange. “I just thought it was really compelling and it kind of just stayed with me,” he said. “And after a while I thought, ‘I wonder what would happen if we made a performance out of this?’”

    Fish doesn’t want to mount a literal recreation of the exchange, instead reaching for something more theatrical. In 1993, Kramer was beamed in from New York while Fauci was in the C-Span studio in Washington, D.C. For the play, Fish will put the two — plus the moderator — in the same room on stage.

    “There’s a moment where Kramer at one point says, ‘You know, I love Tony Fauci,’ and later on he says, ‘Tony, when you talk like that, I hate you.’ And Fauci says, ‘I know you do, Larry.’”

    Source link

  • Stony Brook Medicine launches clinical trials unit in Commack | Long Island Business News

    THE BLUEPRINT:

    • 6,000 sq. ft. Clinical Trials Unit now open at Commack

    • Features 12 exam rooms, infusion bays, and specialized testing labs

    • Supports trials for all ages

    Stony Brook Medicine opened its 6,000-square-foot Clinical Trials Unit at the Advanced Specialty Care at Commack center. Celebrated with a ribbon-cutting on Monday, the unit provides patients with a chance to take part in advanced therapeutic studies and offers physicians and researchers a shared space to conduct clinical trials.

    The space expands Stony Brook’s capacity and research infrastructure to support scientifically rigorous clinical trials that integrate discovery and development to explore new treatments and improve patient outcomes. The facility accommodates trial participants across the lifespan, including children, older adults and individuals with physical disabilities.

    “As we cut the ribbon on this new Clinical Trials Unit here in Commack, we’re celebrating the opening of a new facility, but more importantly, we’re opening doors to discovery and to hope,” Dr. William Wertheim, executive vice president of Stony Brook Medicine, said in a news release about the unit.

    The unit includes 12 examination and consultation rooms, a cardiopulmonary exercise testing facility and a physical performance and gait testing suite. It also features a three-bay infusion area for trials involving chemotherapeutic and intravenous infusions, a procedure room for outpatient trials and a wet lab equipped with a refrigerated centrifuge and a minus-80 F freezer for processing blood and other human samples.

    “This space represents the bridge between groundbreaking research in the laboratory and the patients and families we serve every day, right here in our communities,” Wertheim said.

    The new unit is designed to make advanced clinical trials more accessible to the people served by the health system.

    “For decades, Stony Brook Medicine has been known for translating research from bench to bedside,” Wertheim said. “With this new unit, for the first time, we’re extending that promise beyond the hospital, bringing access to advanced clinical trials closer to where people live and work. It’s a tangible example of how we’re strengthening our connection to the community and ensuring that participation in world-class research is not limited by distance or circumstance.”

    Dr. Peter Igarashi, the dean of the Renaissance School of Medicine at Stony Brook University, shared that sentiment.

    “Academic medicine brings added value in the form of expertise of our academic faculty clinicians, as well as access to state-of-the-art technologies and access to clinical trials, and that’s why we have built this facility,” Igarashi said in the news release. “We look forward to the exciting discoveries that will emerge from the research program for years to come.”

    Now fully operational, the unit is staffed with specialists and principal investigators to manage trials from planning to execution. The unit will conduct studies on a range of conditions, including neurological, cardiovascular, pulmonary, kidney, cancer, mental health and infectious diseases.

    “Currently, we have 260 active clinical trials,” Dr. Susan Hedayati, vice dean for research in the Renaissance School of Medicine at Stony Brook University, said in the news release.

    “These trials account for a vast majority of all of the clinical trials within SUNY academic institutions,” Hedayati added. “By building this Commack Clinical Trials Unit, we’re very enthusiastic that we will have the capacity to significantly and substantially increase this number.”


    Adina Genn

    Source link

  • Research monkeys got loose after a truck overturned on a highway. Their owner, destination, and exact purpose remain shrouded in mystery | Fortune

    The recent escape of several research monkeys after the truck carrying them overturned on a Mississippi interstate is the latest glimpse into the secretive industry of animal research and the processes that allow key details of what happened to be kept from the public.

    Three monkeys have remained on the loose since the crash on Tuesday in a rural area along Interstate 59, spilling wooden crates labeled “live monkeys” into the tall grass near the highway. Since then, searchers in masks, face shields and other protective equipment have scoured nearby fields and woods for the missing primates. Five of the 21 Rhesus macaques on board were killed during the search, according to the local sheriff, but it was unclear how that happened.

    Key details remain shrouded in secrecy

    Mississippi authorities have not disclosed the company involved in transporting the monkeys, where the monkeys were headed or who owns them. While Tulane University in New Orleans has acknowledged that the monkeys had been housed at its National Biomedical Research Center in Covington, Louisiana, it said it doesn’t own them and won’t identify who does.

    An initial report from the sheriff described the monkeys as “aggressive” and carrying diseases such as herpes, adding to the confusion. Tulane later said the monkeys were free of pathogens, but it is still unclear what kind of research the monkeys were used for.

    The questions surrounding the Mississippi crash and the mystery of why the animals were traveling through the South are remarkable, animal advocates say.

    “When a truck carrying 21 monkeys crashes on a public highway, the community has a right to know who owned those animals, where they were being sent, and what diseases they may have been exposed to and harbored simply by being caught up in the primate experimentation industry,” said Lisa Jones-Engel, senior science adviser on primate experimentation with People for the Ethical Treatment of Animals.

    “It is highly unusual — and deeply troubling — that Tulane refuses to identify its partner in this shipment,” Jones-Engel added.

    One thing that is known is that the 2025 Chevrolet Silverado pickup hauling the monkeys was driven by a 54-year-old Cascade, Maryland, man when it ran off the highway into the grassy median area, the Mississippi Highway Patrol said in a statement to The Associated Press. The driver wasn’t hurt, nor was his passenger, a 34-year-old resident of Thurmont, Maryland.

    Confidentiality is built into contracts, blocking information

    Transporting research animals typically requires legally binding contracts that prohibit the parties involved from disclosing information, Tulane University said in a statement to the AP. That’s done for the safety of the animals and to protect proprietary information, the New Orleans-based university said.

    “To the best of Tulane’s knowledge, the 13 recovered animals remain in the possession of their owner and are en route to their original destination,” the statement said.

    The crash has drawn a range of reactions — from conspiracy theories that suggest a government plot to sicken people to serious responses from people who oppose experimenting on animals.

    “How incredibly sad and wrong,” Republican U.S. Rep. Marjorie Taylor Greene said of the crash.

    “I’ve never met a taxpayer that wants their hard-earned dollars paying for animal abuse nor who supports it,” the Georgia congresswoman said in a post on the social platform X. “This needs to end!”

    Tulane center has ties to more than 155 institutions worldwide

    Tulane’s Covington center has received $35 million annually in National Institutes of Health support, and its partners include nearly 500 investigators from more than 155 institutions globally, the school said in an Oct. 9 news release. The center has been funded by NIH since 1964, and federal grants have been a significant source of income for the institution, it said.

    In July, some of the research center’s 350 employees held a ribbon-cutting ceremony to mark the opening of a new 10,000-square-foot office building and a new laboratory at the facility. This fall, the facility’s name was changed from the Tulane National Primate Research Center to the Tulane National Biomedical Research Center to reflect its broader mission, university officials announced.

    Research monkeys have escaped before in South Carolina, Pennsylvania

    The Mississippi crash is one of at least three major monkey escapes in the U.S. over the past four years.

    Last November, 43 Rhesus macaques escaped from a South Carolina compound that breeds them for medical research after an enclosure wasn’t fully locked. Employees from the Alpha Genesis facility in Yemassee, South Carolina, set up traps to capture them. However, some spent two months that winter living in the woods and weathering a rare snowstorm. By late January, the last four escapees were recaptured after being lured back into captivity by peanut butter and jelly sandwiches.

    In January 2022, several cynomolgus macaque monkeys escaped when a truck towing a trailer of about 100 of the animals collided with a dump truck on a Pennsylvania highway, authorities said. The monkeys were headed to a quarantine facility in an undisclosed location after arriving at John F. Kennedy International Airport in New York on a flight from Mauritius, an Indian Ocean island nation, authorities said. A spokesperson for the Centers for Disease Control and Prevention said all of the animals were accounted for within about a day, though three were euthanized for undisclosed reasons.

    Jeff Martin, The Associated Press

    Source link

  • How a tiny retinal implant is helping people regain their sight

    NEWYou can now listen to Fox News articles!

    A new study in The New England Journal of Medicine revealed that the PRIMA brain computer interface (BCI) retinal implant helped people with advanced age-related macular degeneration regain some central vision. The device uses a tiny 2 millimeter by 2 millimeter photovoltaic implant that is only 30 micrometers thick, and thinner than a strand of hair. It sits beneath the retina and works with a special pair of smart glasses. The glasses capture images and send them as near-infrared light to the implant. The implant converts that light into small electrical signals that stimulate the optic nerve. This process mimics how healthy retinal cells normally send visual information to the brain.

    The study followed 38 participants, 32 of whom completed one year of follow-up. Twenty-six patients experienced measurable improvement in vision, which equals about 80% of the group. Many participants could read letters, numbers and even full pages of text again. Although the restored vision is black and white and slightly blurry, the results are remarkable for people who once believed they would never see clearly again.

    WORLD’S THINNEST AI GLASSES FEATURE BUILT-IN AI ASSISTANT

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM newsletter.

    Why this matters for AMD treatment

    Age-related macular degeneration, often called AMD, is one of the leading causes of irreversible blindness in older adults. Until now, available treatments could only slow down vision loss. None of them could restore what had already been lost.

    The PRIMA implant works with smart glasses to bring central vision back to life. (PRIMA by Science)

    The PRIMA implant takes a different approach. It directly replaces the missing function of the retina by turning light into electrical signals. Patients can still use their natural peripheral vision while the implant restores some central vision. This combination creates a more complete visual experience.

    The trial showed that the surgery is generally safe. Most side effects occurred within the first two months and resolved soon after. Importantly, the implant did not reduce the patients’ remaining natural peripheral vision. Researchers call this a major step toward restoring sight rather than only slowing its decline.

    The PRIMA implant was developed by Science Corporation, a brain-computer interface company founded by Max Hodak, who previously cofounded Neuralink. Science Corporation acquired the PRIMA technology from the French firm Pixium Vision, continuing its development toward clinical use.

    EYE DROPS MAY REPLACE READING GLASSES FOR THOSE STRUGGLING WITH AGE-RELATED VISION LOSS

    A visual implant is seen next to a key.

    The tiny chip sits under the retina and turns light into visual signals. (PRIMA by Science)

    What this means for you

    If you or someone you love lives with late-stage AMD, this breakthrough may offer real hope. For the first time, there is a device that can restore some sight instead of only preserving what remains. You may want to talk with your ophthalmologist about upcoming trials or future approval of the PRIMA system in your area. The company behind the technology has already applied for European approval, and a process with the U.S. Food and Drug Administration is underway.

    Regaining even partial central vision can make a big difference. Reading text, recognizing faces or simply moving independently becomes possible again. This progress also shows how fast medical innovation is moving. Patients who were once told that nothing could help may soon have a chance to see again.

    It is also a reminder to stay informed. Treatments that were once experimental are becoming available sooner than expected. Discussing new technologies with your doctor helps you understand timing, eligibility and what kind of results you can realistically expect.

    Woman gets eye exam at doctor's office

    This breakthrough offers new hope for people living with advanced macular degeneration. (PeopleImages/Getty Images)

    Take my quiz: How safe is your online security?

    Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you’ll get a personalized breakdown of what you’re doing right and what needs improvement. Take my Quiz here: CyberGuy.com.

    CLICK HERE TO DOWNLOAD THE FOX NEWS APP

    Kurt’s key takeaways

    The PRIMA retinal implant represents a shift in how scientists and doctors think about blindness caused by AMD. For decades, the focus was on slowing down the disease. Now, researchers are proving that restoration is possible. While this generation of the implant provides limited black and white vision, it gives real, functional sight to people who had none. That alone changes lives. More work remains to improve image clarity, color perception and comfort. Still, this is only the beginning. Future versions of the device and smart glasses may make vision restoration even more effective and accessible.

    If you could regain even part of your sight through new technology, would you take the opportunity and experience the world in a whole new way? Let us know by writing to us at CyberGuy.com.

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM newsletter.

    Copyright 2025 CyberGuy.com. All rights reserved.  

    Source link

  • Doctors on key US health task force accused of prioritizing DEI over evidence-based medicine

    NEWYou can now listen to Fox News articles!

    An “independent” advisory panel of non-federal experts determining which preventative healthcare services insurers must cover is accused of being staffed with doctors who have shown a propensity to prioritize “woke” left-wing diversity, equity and inclusion ideals in their work, as opposed to evidence-based science.

    The U.S. Preventative Services Task Force (USPSTF), an all-volunteer panel of doctors who serve four-year terms appointed by the Secretary of Health, is made up of experts in preventative medicine, which includes services like screening tests, immunizations, behavioral counseling, and medications that can prevent the development or worsening of health conditions. One of the task force’s primary functions is to weigh the efficacy and cost-benefit of such preventative care services, recommendations for which are then used to shape what preventative care services insurance providers must cover.

    The task force’s ability to make these healthcare recommendations, coupled with what appears to be a membership largely made up of left-wing, DEI proponents, has raised concerns about how the task force could be impacting healthcare. 

    The Wall Street Journal reported in July that sources with knowledge of Health Secretary Robert F. Kennedy Jr.’s thinking said he was planning to dismiss all 16 members of the USPSTF for being too “woke.” 

    NEW MEDICAL POLICY CENTER COMBATS WOKENESS IN MEDICINE, LAUNCHING LANDMARK RANKING OF TOP SCHOOLS

    RFK Jr. speaks at the 2025 Rx and Illicit Drug Summit at Gaylord Opryland Resort and Convention Center in Nashville, Tenn., Thursday, April 24, 2025. (© Nicole Hester / The Tennessean / USA TODAY NETWORK)

    “HHS has been made aware of the ideological issues with members of the USPSTF raised by letters from Senate Republicans, members of the GOP Doctors Caucus, and a large group of physicians including Associations of American Physicians and Surgeons, America’s Frontline Doctors, and the Pennsylvania Direct Primary Care Association. HHS is troubled by these allegations and is investigating further,” Emily Hilliard, a Health and Human Services Department spokesperson told Fox News Digital when asked about Kennedy’s plans for the future of the current USPSTF.

    Meanwhile, others, including the GOP Doctors Caucus and major physician groups including the Association of American Physicians and Surgeons, have also raised alarm bells about potential left-wing bias at the USPSTF. One group that has also raised alarm bells about the USPSTF is the conservative watchdog group known as the American Accountability Foundation (AAF), which just released a new report claiming the USPSTF “has been thoroughly hijacked by left-wing partisans for the purpose of weaponizing science to spread leftist ideology.”

    The AAF report points to Dr. Michael Silverstein, the task force’s current chairman, who, in 2023, said that USPSTF is “dedicated to … addressing critical issues of health equity” after he was re-appointed to the task force’s leadership team under the Biden administration. As Vice Chair of the task force in 2023, Silverstein co-authored an annual report to Congress highlighting a new partnership with the Gay and Lesbian Medical Association (GLMA) aimed at helping the task force be more “inclusive.”

    The partnership, according to the report to Congress, was meant to help develop “new recommendations on screening for anxiety disorders, and other conditions that affect LGBTQ+ communities to enhance the health, wellness, and quality of life of their patients.”

    Other recommendations from the USPSTF that have come down in the last several years include a 2022 recommendation denoting the need for physicians to consider race when screening for anxiety in children and adolescents. A more recent recommendation, published in April, said that doctors should pay special attention to breastfeeding in black mothers due to the “lasting psychological impact and stigma of enslaved Black women being forced to act as wet nurses.” 

    I’M A GENDER DETRANSITIONER. I TOLD THE FTC HOW DOCTORS ABUSED THEIR POWER OVER ME     

    Denver-Health

    Denver, CO – APRIL 25 : Medical doctor Alia Broman, right, examines a 6 years old patient at Denver Health in Denver, Colorado on Thursday, April 25, 2024.  (Hyoung Chang/The Denver Post))

    Meanwhile, a 2021 report from the USPSTF, on addressing sex and gender when making preventative healthcare recommendations, included an analysis of how gender-specific terminology, as opposed to “gender-neutral” terminology, could play a role in addressing the needs of “diverse populations.” Think “pregnant people” versus “pregnant mother,” a switch that eventually became part of the task force’s official guidelines. 

    “To advance its methods, the USPSTF reviewed its past recommendations that included the use of sex and gender terms, reviewed the approaches of other guideline-making bodies, and pilot tested strategies to address sex and gender diversity,” the report states. “Based on the findings, the USPSTF intends to use an inclusive approach to identify issues related to sex and gender at the start of the guideline development process; assess the applicability, variability, and quality of evidence as a function of sex and gender; ensure clarity in the use of language regarding sex and gender; and identify evidence gaps related to sex and gender.”

    Another major achievement towards the task force’s mission to advance “health equity” was the release of a 2024 “Health Equity Framework” aimed at embedding gender theory and other left-wing ideologies into its operations. 

    HOW UNIVERSITY INDOCTRINATION TURNED DEADLY, AND WHY ONE SCHOLAR SAYS IT’S ONLY GETTING WORSE  

    In addition to the work the task force has done, its members also have an extensive history of publishing research that focuses on “health equity” and other DEI components, such as how race impacts certain health outcomes, or how to address sex and gender when making recommendations for clinical preventative services.

    “National Institutes of Health Pathways to Prevention Workshop: Achieving Health Equity in Preventive Services,” is the title of a scientific research report co-authored by task force rank-and-file member, Dr. Sandra Millon Underwood. “Further Incorporating Diversity, Equity, and Inclusion Into Medical Education Research,” and “Health Equity Starts with Us: Recommendations from the Indiana Clinical and Translational Sciences Institute Racial Justice and Health Equity Task Force,” were also reports co-authored by members of the USPSTF.

    “Antiracist initiatives, such as incorporating community-support persons (e.g., lay doulas) into maternity care for Black people, can reduce disparities in outcomes by addressing both interpersonal racism and the lack of workforce diversity caused by structural racism,” stated a May 2024 research paper co-authored by USPSTF rank-and-file member Dr. Alicia Fernandez.

    Doctor seen next to Diversity, Equity and Inclusion image

    The U.S. Preventative Services Task Force (USPSTF) has been accused of being infiltrated by “woke” leftists, with sources familiar with Heath Secretary Robert F. Kennedy saying he has plans to fire all 16 of them.  (iStock; Getty Images)

    Members of the supposedly “independent” USPSTF have also used their positions of expertise to fight Trump administration priorities as well, such as those around abortion and research funding reforms. 

    For example, Dr. David Chelmow, another task force member, has appeared in several physician-backed American Civil Liberties Union memos about efforts opposing the Trump administration, including one challenging Trump’s efforts to implement greater protections around the mail-order abortion drug called mifepristone, which many pro-life OBGYN’s have warned is dangerous if not dispensed in-person. In March, Dr. Carlos Roberto Jaen, another task force member, signed a letter alongside 1,900 others accusing the Trump administration of weakening US research capacity and endangering Americans.

    WHAT’S REALLY IN YOUR FOOD? NEW CAMPAIGN PUSHES FOR NATIONAL INGREDIENT TRANSPARENCY 

    When making recommendations for preventative care services, the USPSTF assigns a letter grade, A, B, C, D, or I. 

    Any service given an “A” or “B” grade, is required to be covered by private insurers under a mandate in the Affordable Care Act (ACA). These grades are also tied to coverage requirements for public insurers, like Medicare and Medicaid. 

    In 2019, the task force gave the precautionary anti-HIV drug Preexposure Prophylaxis (PrEP) an “A” grade, guidelines for which were later clarified in 2023. The task force’s current Vice Chair, Dr. John Wong, also co-authored a 2017 paper on how scaling-up the use of PrEP can help reduce the prevalence of HIV among gay men. But, according to AAF, the active promotion of PrEP creates an atmosphere of dangerous sexual activity that risks public health dangers due to what the foundation says is promotion of risky sexual behaviors. Additionally, at least one Christian-owned business has argued that forcing insurance providers to cover medication that promotes risky sexual behaviors violates their rights.

    Earlier this summer, the Supreme Court weighed in on whether the USPSTF’s authority to compel coverage of preventative healthcare it gives either an “A” or “B” grade was unconstitutional. The group that brought the case, Braidwood Management Inc., initially objected on religious grounds to the ACA requirement that insurance providers cover certain HIV-prevention medications for which the task force has issued an “A” recommendation, specifically PrEP. However, the case ultimately morphed into a question over the legitimacy of USPSTF’s recommendation authority, and whether the circumvention of Senate approval for its members was allowed by the Constitutions Article II clause on advise and consent.

    Supreme Court

    The facade of the Supreme Court building at dusk is shown in this photo. (Drew Angerer/Getty Images)

    CLICK HERE TO GET THE FOX NEWS APP 

    Both the Biden and Trump administrations have taken up the argument that the Health Secretary alone has ultimate control over whether to appoint or fire USPSTF members. The Trump administration also argued in its briefs to the High Court that the Secretary had the authority to block, or rescind, task force recommendations as well, according to SCOUTS Blog.   

    Ultimately, the Supreme Court voted 6-3, in favor of the federal government’s argument that the appointment process for the USPSTF, and therefore its legitimacy, did not violate the Constitution.

    Shortly after the Supreme Court’s decision in the Braidwood case, Health Secretary Kennedy reportedly postponed a long-scheduled task force meeting of the USPSTF, which was the same move he made before firing every member of the Advisory Committee on Immunization Practices (ACIP), the main federal entity that helps craft federal vaccine policy. Kennedy has long been a critic of conventional vaccination policies and practices.    

    The Wall Street Journal reported in July, not long after the Supreme Court’s decision in the Braidwood case, that sources familiar with Kennedy’s thinking said he was planning to dismiss all 16 members of the USPSTF for being too “woke.”

    Source link

  • New vitamin compound shows promise for reversing Alzheimer’s damage to the brain

    NEWYou can now listen to Fox News articles!

    An enhanced version of vitamin K could help reverse brain damage from Alzheimer’s disease, a study has found.

    Alzheimer’s and many other neurodegenerative diseases are marked by a loss of brain neurons. While most medications treat only the symptoms, researchers from the Department of Bioscience and Engineering at Shibaura Institute of Technology in Japan set out to determine whether a new approach could replace the lost cells.

    Vitamin K is an essential nutrient that aids with blood clotting, bone health and other important functions in the body, according to the National Institutes of Health. 

    SIMPLE DIET CHANGE MAY SUPPORT GUT HEALING FOR CANCER SURVIVORS, RESEARCHERS SAY

    While it has been shown to support brain protection and neuron creation, the natural forms of vitamin K — including menaquinone-4 (MK-4) — might not be powerful enough to effectively treat neurodegenerative diseases, experts say.

    An enhanced version of vitamin K could help reverse brain damage from Alzheimer’s disease, a study has found. (iStock)

    To boost its potency, researchers from the Department of Bioscience and Engineering at Shibaura Institute of Technology in Japan developed new, stronger forms of the vitamin.

    They did this by creating 12 new versions of vitamin K and combining it with retinoic acid, an active metabolite of vitamin A that helps brain cells grow and develop.

    CLICK HERE TO GET THE FOX NEWS APP

    In lab tests, the new lab-made versions of vitamin K were about three times more effective than natural vitamin K at helping immature brain cells develop into neurons, according to study co-lead Associate Professor Yoshihisa Hirota.

    Senior woman vitamins

    Vitamin K is an essential nutrient that aids with blood clotting, bone health and other important functions in the body. (iStock)

    The new vitamin K compound was also shown to successfully cross the blood-brain barrier in animal tests. 

    Another important benefit, the researchers noted, is that the new molecules retained the same benefits of vitamin K and vitamin A while showing stronger brain-cell activity.

    CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

    The findings were published in the journal ACS Chemical Neuroscience.

    Doctor analyzing brain scan

    The new vitamin K compound was also shown to successfully cross the blood-brain barrier in animal tests.  (iStock)

    “Since neuronal loss is a hallmark of neurodegenerative diseases such as Alzheimer’s disease, these analogues may serve as regenerative agents that help replenish lost neurons and restore brain function,” Hirota said in a press release.

    TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

    Looking ahead, the research team plans to test the new compounds in animal and human studies, in hopes that this could lead to a new approach for slowing or repairing brain degeneration for patients with neurodegenerative diseases. 

    CLICK HERE FOR MORE HEALTH STORIES

    “A vitamin K-derived drug that slows the progression of Alzheimer’s disease or improves its symptoms could not only improve the quality of life for patients and their families, but also significantly reduce the growing societal burden of healthcare expenditures and long-term caregiving,” Hirota added.

    Source link

  • UC Santa Barbara develops new soft robotic system for emergency intubation procedures

    NEWYou can now listen to Fox News articles!

    When someone stops breathing, the clock starts ticking. First responders often need to get air into the lungs fast, and one of the most reliable ways is to slide a tube into the windpipe. This process, called intubation, keeps the airway open so that oxygen can flow again.

    Here’s the catch: intubation is incredibly hard. Even trained doctors can struggle, and every extra second puts the patient at greater risk. Now, researchers at UC Santa Barbara have designed a soft robotic device that could change how first responders handle these emergencies. It helps guide the breathing tube into place quickly, safely, and with far less training than traditional methods.

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide – free when you join my CYBERGUY.COM newsletter.

    Why breathing tubes are so tough to place

    Our bodies are built to keep food and foreign objects out of the lungs. A small flap called the epiglottis blocks the windpipe during swallowing, and the path into the trachea is narrow and curved. To get around these obstacles, current tools are rigid. Medics have to lift the epiglottis with a metal scope and carefully angle the tube forward. If it slips into the esophagus instead, oxygen goes to the stomach instead of the lungs. “Traditional tools must be stiff so you can push them, and they only turn by pressing on sensitive tissue,” explained Elliot Hawkes, professor of mechanical engineering at UCSB.

    DANGEROUS HEART CONDITIONS DETECTED IN SECONDS WITH AI STETHOSCOPE

    Even trained doctors can struggle with intubation. (Universal Images Group/Getty Images)

    How the soft robot works

    The new system, called the soft robotic intubation system (SRIS), takes a gentler approach. First, a curved guide sits at the back of the throat. Then a soft inflatable tube slowly unrolls from the inside out as it advances. Instead of being forced in, it naturally follows the right path into the windpipe. This reduces friction, lowers the risk of injury and adapts to different body shapes automatically. “This growing paradigm naturally accounts for minor variations in anatomy,” said lead author David Haggerty, a recent UCSB Ph.D. graduate.

    What the tests show

    The results are eye-opening:

    • Experts had a 100% success rate.
    • Paramedics and EMTs reached a 96% success rate with just five minutes of training.
    • Non-experts placed the tube in an average of 21 seconds, less than half the time needed with advanced video laryngoscopes.

    Why this device could save more lives

    Millions of emergency intubations happen in the U.S. each year. Many take place in chaotic, low-light or stressful situations where current tools don’t always work. A device that makes the process easier could be a lifesaver for:

    • Paramedics at accident scenes
    • Military medics in combat zones
    • Doctors in hospitals with limited equipment

    AI VIDEO TECH FAST-TRACKS HUMANOID ROBOT TRAINING

    A row of ambulances parked at a hospital emergency bay, ready for dispatch.

    In trials, both experts and non-experts achieved faster and more successful intubations using the new airway management system — advancing emergency response efficiency. (Kurt Knutsson)

    The UCSB team is now preparing for clinical trials and FDA approval.

    HOW MICRO-ROBOTS MAY SOON TREAT YOUR SINUS INFECTIONS

    What this means for you

    If this device lives up to its early promise, it could mean that more patients survive emergencies where breathing stops. For families, it means a higher chance that first responders can keep loved ones alive until they reach the hospital. For medics, it offers a safer, faster tool when seconds truly matter.

    Take my quiz: How safe is your online security?

    Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you’ll get a personalized breakdown of what you’re doing right and what needs improvement. Take my Quiz here: Cyberguy.com.

    Kurt’s key takeaways

    Breathing is life, yet securing an airway is one of the toughest jobs in emergency care. This soft robotic system may help turn a high-risk procedure into something more predictable and safe. While more testing is still ahead, the early data shows how robotics could make a lifesaving difference for patients everywhere.

    Medical professionals practice artificial respiration on a training mannequin in a hospital setting.

    Medical staff participate in hands-on training to practice emergency response and resuscitation techniques using a lifelike simulation mannequin. (Universal Images Group/Getty Images)

    CLICK HERE TO GET THE FOX NEWS APP

    Would you feel more confident knowing first responders in your community had access to this kind of lifesaving robot? Let us know by writing to us at Cyberguy.com.

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide – free when you join my CYBERGUY.COM newsletter.

    Copyright 2025 CyberGuy.com. All rights reserved.  

    Source link

  • Trio Wins Nobel Prize in Medicine for Discoveries on Immune System

    Immunologists Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi were awarded the Nobel Prize in Physiology or Medicine for discoveries that spurred the development of new treatments for cancer and autoimmune diseases and laid the foundation for a new field of research.

    The trio identified a core feature of how the immune system functions and keeps itself in-check: regulatory T-cells. They prevent other immune cells from attacking our own bodies and developing autoimmune conditions including Type 1 diabetes and rheumatoid arthritis. Based on this fundamental knowledge, clinical trials are ongoing to test therapies for autoimmune diseases, cancer and following organ transplantation.

    Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

    Brianna Abbott

    Source link

  • Prostate cancer patients see longer survival with new combination drug

    NEWYou can now listen to Fox News articles!

    A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment.

    This approach could also help delay the need for hormone therapy, which can have burdensome side effects.

    The findings, which were presented at the annual American Society for Radiation Oncology (ASTRO) meeting this week, showed that combining a targeted radioactive drug with standard radiation therapy more than doubled the amount of time patients remained free of disease progression.

    NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%

    The study focused on men with a form of cancer recurrence where the disease had returned in only a few isolated spots. Traditionally, this has been treated with a type of focused radiation called stereotactic body radiation therapy, a highly precise type of radiation therapy used to treat tumors in the body.

    The UCLA-led team wanted to determine whether adding a PSMA-targeted radioligand therapy, a radioactive drug that zeroes in on cancer cells, would be more effective, according to a press release.

    The study focused on men with a form of cancer recurrence where the disease had returned in only a few isolated spots.  (iStock)

    The researchers enrolled 92 men with recurring prostate cancer into the trial. Half received radiation alone, while the other half received the new drug plus radiation.

    The men who received both treatments stayed cancer-free for a median of nearly 18 months, compared to about seven months for those who got radiation alone.

    CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

    “This is the first randomized trial to show that PSMA-targeting radioligand can significantly delay progression when added to metastasis-directed radiation,” Dr. Amar Kishan, executive vice chair of radiation oncology at UCLA and lead author of the study, told Fox News Digital.

    Doctor talking to a patient in a consultation at the office

    One of the biggest benefits is the potential for patients to delay starting hormone therapy, according to the lead researcher. (iStock)

    Kishan called the work “a great example of true collaboration between radiation oncology and nuclear medicine.”

    CLICK HERE TO GET THE FOX NEWS APP

    One of the biggest benefits is the potential for patients to delay starting hormone therapy, according to Kishan. While this is a common next step, it often brings side effects like fatigue, bone loss and mood changes.

    “It gives patients more time before needing hormonal therapy,” Kishan said. “Avoiding or delaying hormonal therapy consistently benefits quality of life.”

    Man waiting for MRI scan

    “This is the first randomized trial to show that PSMA-targeting radioligand can significantly delay progression when added to metastasis-directed radiation,” said the lead researcher. (iStock)

    Despite the improvements, the cancer eventually came back for many of the patients. 

    “There is always room for improvement,” Kishan noted. “There were still progression events … so there may be ways to optimize the treatment further.”

    MORE IN HEALTH NEWS

    The new drug, called 177Lu-PNT2002, is not yet FDA-approved for use at this stage of disease.

    For now, Kishan recommends that men who are experiencing a spread of their prostate cancer to areas outside the prostate should “seek a consultation with a radiation oncologist to explore options.”

    Source link

  • Steep Trump cuts haven’t effectively ended medical research

    President Donald Trump has made historically large cuts to medical research, some of them aimed at ending what he refers to as diversity, equity and inclusion in federally funded studies. His administration is proposing more: Overall funding for the National Institutes of Health would return to its 2007 level if Trump’s budget proposal were to be enacted. A recent New York Times story highlighted Trump’s billions in proposed National Cancer Institute cuts and carried the headline, “Trump Is Shutting Down the War on Cancer.”

    In the midst of a fight with Republicans over spending and a possible government shutdown, House Minority Leader Hakeem Jeffries, D-N.Y., criticized the Trump administration’s efforts to cut back medical research funding during a Q&A with reporters.

    “Republicans have effectively ended medical research in the United States of America,” Jeffries said Sept. 24.

    Has the Trump administration really ended medical research? While a substantial amount has disappeared, and more could be on the way out if Trump gets his way, Jeffries exaggerated the outlook, even allowing for his “effectively” caveat. Billions of dollars would remain even in the most austere scenario, and there’s uncertainty about whether his most severe proposed cuts will receive congressional approval. 

    Even after proposing substantial cuts to the budget of the National Institutes of Health — the main engine funding U.S. medical research — Trump’s proposal would give the institutes $27 billion for fiscal year 2026. 

    Sign up for PolitiFact texts

    And Trump’s proposal is not final; Congress could increase that amount. Some experts call that scenario likely.

    “The appropriations language making its way through Congress is much less draconian, so it may be too early to know where all this is going to land,” said Richard Frank, a senior fellow at the Brookings Institution, a Washington, D.C., think tank.

    Jeffries’ office did not provide additional evidence for his statement.

    What cuts has Trump made so far?

    Trump’s cuts so far take several forms, said Joshua Weitz, a University of Maryland biology professor who co-founded the Science and Community Impacts Mapping Project, which is tracking the impacts of federal funding cuts nationally. Some of these cutbacks are being challenged in court.

    • Weeks after Trump’s inauguration, the National Institutes of Health announced major cuts to “indirect costs” —  funds that pay for facilities, safety and grant administration. It capped indirect costs for labs working on NIH grants at 15%. Previously, the average rate was about 28%, and sometimes above 60%.

    • The White House has terminated thousands of research grants worth approximately $5 billion. Some of these were canceled for being related to diversity, equity and inclusion, a top target of the administration, such as a $3.8 million Asian Bipolar Genetics Network study to a $1.05 million Alzheimer’s and dementia study focusing on Black Americans. Others were related to administration efforts to punish elite universities for allegedly allowing antisemitism on campus, leading to hiring freezes and holds on clinical trials, Harvard University economist David Cutler and Harvard economist Edward Glaeser co-wrote a recent paper in JAMA Health Forum. “A fraction of these grants have been reinstated, but science does not turn on and off like a spigot,” Weitz said. “Interrupting research leads to wasted studies, risks projects, and is already causing job loss.”

    • Through early April, the NIH ousted 1,200 employees, and granted an unknown number of retirements and resignations. At the Food and Drug Administration, which approves drugs, thousands of jobs have been eliminated.

    • The president’s budget proposal would cut NIH funding from about $45 billion to about $27 billion. That’s a roughly 39% cut for a budget item that in recent decades has almost always increased from year to year. The proposed budget would eliminate the National Institutes for Nursing Research, the National Center for Complementary and Integrative Health, the Fogarty International Center, and the National Institute on Minority Health and Health Disparities.

    The consequences of these cuts could be significant. 

    “Our research shows that while cutting NIH funding may appear to save money in the short term, it can trigger a chain of effects that increase long-term health care costs and slow the development of new treatments and public health solutions over time,” Harvard University health policy and data specialists Mohammad S. Jalali and Zeynep Hasgül wrote for The Conversation. 

    Between 2010 and 2019, all but two of the 356 drugs approved by the Food and Drug Administration received some NIH funding, one study found. So any cuts could reduce the number of drugs in the pipeline, experts say.

    Once all the follow-on impacts reverberate throughout the U.S. economy and health care system, the cuts could prompt an “$8 trillion health care catastrophe,” Cutler and Glaeser wrote. They estimated that the losses from reduced health would be 16 times greater than the proposed budgetary savings.

    Despite the cuts, medical research is here to stay

    The cuts are extensive but do not end U.S. medical research.

    Trump’s slashed NIH budget would still spend more than $27 billion in fiscal year 2026. 

    “Novel biomedical discoveries that enhance health and lengthen life are more vital than ever to our country’s future,” the agency said in its budget proposal. “NIH research is critical to protect national security and sustain the United States’ scientific competitiveness, globally.”

    The president’s proposal highlighted initiatives on nutrition, obesity, heart disease, diabetes, asthma, autism, and cancer, all priorities of Health and Human Services Secretary Robert F. Kennedy Jr.

    The FDA would receive a modest budgetary bump under Trump’s budget proposal, to almost $6.8 billion. 

    Despite the Republican majority’s generally close alignment with Trump’s policy agenda, Congress is on record rejecting his proposed medical research cuts, at least in the preliminary stage. 

    The Senate and House appropriations committees have voted for modest increases in NIH’s budget rather than Trump’s large cuts. They also voted to fund CDC and FDA at higher levels than Trump set out in his budget proposal.

    These increases are not guaranteed; they will have to go through negotiations between lawmakers and the president before final passage. 

    “Congress is likely to approve much smaller cuts than the Administration had proposed,” said Sherry Glied, a professor at New York University’s Robert F. Wagner Graduate School of Public Service.

    Our ruling

    Jeffries said, “Republicans have effectively ended medical research in the United States of America.”

    Trump has proposed severe cuts to medical research at the National Institutes of Health and other agencies, including caps on indirect costs for grantees’ labs, terminated grant funding and staff reductions. But this is not tantamount to effectively ending U.S. medical research.

    Even if Trump gets his way on a 39% cut to NIH’s budget in 2026, the institutes would still have more than $27 billion to spend in fiscal year 2026.

    Trump’s fellow Republicans in Congress may not go along with cuts on the scale the president proposed. Appropriations committees in both the Senate and the House have already rejected Trump’s steep cuts on medical research.

    Trump’s medical research cuts are real and sweeping, but they have not “effectively ended medical research.” We rate the statement Mostly False.

    Source link

  • California moves to distance itself from CDC on vaccines, considers creating its own agency

    UPDATES AS THEY COME IN. OTHER NEWS, RIGHT NOW, HEALTH OFFICIALS ARE FOCUSING ON VACCINE DEADLINES. THIS WEEK, A CDC COMMITTEE WILL CONSIDER POSSIBLE CHANGES TO RECOMMENDATIONS TOMORROW. AND NOW THE STATE OF CALIFORNIA IS CONSIDERING DISTANCING ITSELF FROM THE FEDERAL GOVERNMENT’S GUIDELINES. THE POTENTIAL CHANGE IN GUIDANCE COMES AS THE RECENTLY FIRED CDC DIRECTOR WARNS THOSE CHANGES MAY NOT BE BASED ON SCIENCE. WE HAVE TEAM COVERAGE FOR YOU OF WHAT YOU NEED TO KNOW. ASHLEY ZAVALA HAS THE CHANGE IN STATE VACCINATION GUIDELINES, BUT WE START WITH JACKIE DEFUSCO LIVE ON CAPITOL HILL FOR US WITH A MESSAGE FROM THE FORMER CDC DIRECTOR. YEAH. HEY THERE, ANDREA CURTIS ON CAPITOL HILL TODAY, THE FORMER CDC DIRECTOR, SUSAN MONAREZ, CLAIMED THAT SHE WAS FIRED IN PART FOR ESSENTIALLY REFUSING TO PRE-APPROVE VACCINE RECOMMENDATIONS WITHOUT SEEING THE SCIENTIFIC EVIDENCE FIRST. SHE TOLD SENATORS THAT SHE IS NERVOUS ABOUT WHAT’S TO COME. TAKE A LISTEN. BASED ON WHAT I OBSERVED DURING MY TENURE, THERE IS A REAL RISK THAT RECOMMENDATIONS COULD BE MADE RESTRICTING ACCESS TO VACCINES FOR CHILDREN AND OTHERS IN NEED WITHOUT RIGOROUS SCIENTIFIC REVIEW, WITH NO PERMANENT CDC DIRECTOR IN PLACE, THOSE RECOMMENDATIONS COULD BE ADOPTED. HEALTH SECRETARY ROBERT F KENNEDY JR HAS DENIED THAT HE ORDERED MONAREZ TO RUBBER STAMP VACCINE RECOMMENDATIONS. BUT THE DISPUTE COMES AS THE CDC’S INFLUENTIAL ADVISORY PANEL, WHOSE MEMBERS WERE RECENTLY REPLACED BY KENNEDY, IS SET TO CONVENE TOMORROW TO CONSIDER POSSIBLE CHANGES TO GUIDANCE ON COVID 19, CHICKENPOX AND HEPATITIS B SHOTS. TELLING LAWMAKERS THAT SHE HAS NOT SEEN ANY DATA AT THIS POINT TO SUPPORT CHANGING ELIGIBILITY CRITERIA. FORMER CDC CHIEF MEDICAL OFFICER DEBORAH OURY, WHO RECENTLY RESIGNED, ALSO TESTIFIED TODAY. AND SHE SAID THAT ONE OF KENNEDY’S POLITICAL ADVISERS TOLD HER NOT TO INCLUDE INFORMATION THAT COULD SUPPORT MAINTAINING HEPATITIS B SHOTS FOR NEWBORNS TO PREVENT THE DEADLY DISEASE FROM SPREADING FROM THE MOTHER. YOU’RE SUGGESTING THAT THEY WANTED TO MOVE AWAY FROM THE BIRTH DOSE, BUT THEY WERE AFRAID THAT YOUR DATA WOULD SAY THAT THEY SHOULD RETAIN IT. IT. WHAT DO WE DO NOW? IT’S STILL UNCLEAR AT THIS POINT HOW EXACTLY THE ADVISORY PANEL WILL VOTE LATER THIS WEEK, BUT SOME MEMBERS IN THE PAST HAVE QUESTIONED THE NECESSITY OF THE HEPATITIS B SHOT FOR NEWBORNS, AND HAVE ALSO SUGGESTED THAT THERE SHOULD BE A MORE CONSERVATIVE SET OF VACCINE RECOMMENDATIONS FOR THE COVID 19 SHOT, REGARDLESS OF WHAT THAT PANEL RECOMMENDS. ULTIMATELY, THE ACTING CDC DIRECTOR, JIM O’NEILL, WILL NEED TO SIGN OFF BEFORE THEY BECOME OFFICIAL LIVE ON CAPITOL HILL. I’M JACKIE DEFUSCO, KCRA THREE NEWS. JACKIE, THANK YOU. AND CLOSER TO HOME, CALIFORNIA LEADERS TODAY CONTINUE TO DISTANCE THE STATE FROM THE CDC WITH A SERIES OF ANNOUNCEMENTS. KCRA THREE POLITICAL DIRECTOR ASHLEY ZAVALA EXPLAINS THE ACTION GOVERNOR GAVIN NEWSOM TOOK TODAY. WELL, THIS COMES AS THE STATE CONTINUES TO CLASH WITH THE FEDERAL GOVERNMENT OVER VACCINES AND SCIENCE. OVERALL. TODAY, NEWSOM, ALONGSIDE THE GOVERNORS OF OREGON, WASHINGTON AND HAWAII, ROLLED OUT THEIR OWN VACCINE RECOMMENDATIONS FOR THE WINTER. THE GROUP IS ALSO NOW KNOWN AS THE WEST COAST HEALTH ALLIANCE. AS OF A COUPLE OF WEEKS AGO, THE RECOMMENDED SHOTS INCLUDE THE COVID 19 SHOT, FLU AND RSV SHOTS. THE GOVERNOR TODAY ALSO SIGNED A NEW STATE LAW THAT ALLOWS CALIFORNIA TO TAKE VACCINE RECOMMENDATIONS FROM MEDICAL GROUPS OUTSIDE OF THE CDC. THIS COMES AFTER ROBERT F KENNEDY JR FIRED ALL 17 MEMBERS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES AND REPLACE THEM WITH VACCINE SKEPTICS. THE TRUMP ADMINISTRATION LOOSENED RECOMMENDATIONS AROUND THE COVID 19 VACCINE. ALSO IN A STATEMENT, THE WEST COAST GOVERNOR SAID, OUR STATES ARE UNITED IN PUTTING SCIENCE, SAFETY AND TRANSPARENCY FIRST AND IN PROTECTING FAMILIES WITH CLEAR, CREDIBLE VACCINE GUIDANCE. THE WEST COAST HEALTH ALLIANCE STANDS UNITED IN PROTECTING PUBLIC HEALTH AND ALWAYS PUTTING SAFETY BEFORE POLITICS. MEANWHILE, A SPOKESPERSON FOR THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES SAID DEMOCRAT RUN STATES THAT PUSHED UNSCIENTIFIC SCHOOL LOCKDOWNS, TODDLER MASK MANDATES AND DRACONIAN VACCINE PASSPORTS DURING THE COVID ERA COMPLETELY ERODED THE AMERICAN PEOPLE’S TRUST IN PUBLIC HEALTH AGENCIES. ACIP REMAINS THE SCIENTIFIC BODY GUIDING IMMUNIZATION RECOMMENDATIONS IN THIS COUNTRY. AND HHS WILL ENSURE POLICY IS BASED ON RIGOROUS EVIDENCE AND GOLD STANDARD SCIENCE, NOT THE FAILED POLITICS OF THE PANDEMIC. END QUOTE. NOW, SEPARATELY FROM THE GOVERNOR’S ANNOUNCEMENT TODAY, SOME DEMOCRATIC STATE LAWMAKERS AND LABOR GROUPS LAUNCHED AN EFFORT THAT WOULD ESSENTIALLY CREATE CALIFORNIA’S OWN CDC AND FOUNDATION FOUNDATION TO FUND MEDICAL RESEARCH. THIS WOULD FIRST NEED TO PASS AT THE STATE CAPITOL, THOUGH, BEFORE GOING TO VOTERS IN A BALLOT MEASURE IN NOVEMBER OF 2026. SO HOW MUCH MONEY ARE THEY EXPECTING TO SPEND ON THIS PROPOSAL? YEAH, ESSENTIALLY THEY’RE GOING TO ASK CALIFORNIA VOTERS TO APPROVE A MEASURE THAT WOULD INVOLVE BORROWING $23 BILLION IN BONDS. WE WILL HAVE A LOT MORE ON THIS AT FIVE. A LOT OF QUESTIONS AROUND THA

    California’s Democratic leaders on Wednesday announced a series of efforts to distance the state from President Donald Trump’s Centers for Disease Control and Prevention as the state and federal government continue to clash over vaccines and science. Gov. Gavin Newsom on Wednesday signed legislation that allows the state to set future immunization guidance on credible, independent medical organizations instead of the CDC. Those organizations could include but are not limited to the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians. Also on Wednesday, the governor and the California Department of Public Health, along with other West Coast governors, rolled out vaccine recommendations for the upcoming winter, countering advice from the CDC. The recommendations include the COVID-19 shot, flu shot, and RSV vaccine. It comes two weeks after the leaders of California, Oregon, Washington and Hawaii established the West Coast Health Alliance to rebuke the Trump administration’s policies. States typically follow guidance from the CDC, but the Democratic leaders established the alliance after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. fired all 17 members of the federal panel that advises on immunization practices and replaced them with vaccine skeptics. “Our states are united in putting science, safety, and transparency first — and in protecting families with clear, credible vaccine guidance. The West Coast Health Alliance stands united in protecting public health and always putting safety before politics,” the governors said in a joint statement. Separately from Newsom’s announcement Wednesday, labor groups and some California lawmakers announced an effort to try to establish their own CDC and foundation to fund medical research. The proposal specifically would involve borrowing $23 billion in bonds. The legislation, known as Senate Bill 607, would first need to pass the state Legislature before giving voters the final say on the November ballot in 2026. “In communities across California, families are counting on science to deliver cures, protect our health, and prepare us for the challenges of the future,” said Assemblymember José Luis Solache, D-Lynwood. “Donald Trump’s cuts threaten not just research, but the lives of our loved ones. This measure makes clear that Californians will take control of our future and invest in life-saving research – because our families, our health, and our economy are too important to leave in the hands of Washington politicians playing games with people’s lives.””Democrat-run states that pushed unscientific school lockdowns, toddler mask mandates, and draconian vaccine passports during the COVID era completely eroded the American people’s trust in public health agencies,” a statement from the U.S. Department of Health and Human Services read. “ACIP remains the scientific body guiding immunization recommendations in this country, and HHS will ensure policy is based on rigorous evidence and Gold Standard Science, not the failed politics of the pandemic.” See more coverage of top California stories here | Download our app | Subscribe to our morning newsletter | Find us on YouTube here and subscribe to our channel

    California’s Democratic leaders on Wednesday announced a series of efforts to distance the state from President Donald Trump’s Centers for Disease Control and Prevention as the state and federal government continue to clash over vaccines and science.

    Gov. Gavin Newsom on Wednesday signed legislation that allows the state to set future immunization guidance on credible, independent medical organizations instead of the CDC. Those organizations could include but are not limited to the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians.

    Also on Wednesday, the governor and the California Department of Public Health, along with other West Coast governors, rolled out vaccine recommendations for the upcoming winter, countering advice from the CDC. The recommendations include the COVID-19 shot, flu shot, and RSV vaccine.

    It comes two weeks after the leaders of California, Oregon, Washington and Hawaii established the West Coast Health Alliance to rebuke the Trump administration’s policies. States typically follow guidance from the CDC, but the Democratic leaders established the alliance after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. fired all 17 members of the federal panel that advises on immunization practices and replaced them with vaccine skeptics.

    “Our states are united in putting science, safety, and transparency first — and in protecting families with clear, credible vaccine guidance. The West Coast Health Alliance stands united in protecting public health and always putting safety before politics,” the governors said in a joint statement.

    Separately from Newsom’s announcement Wednesday, labor groups and some California lawmakers announced an effort to try to establish their own CDC and foundation to fund medical research. The proposal specifically would involve borrowing $23 billion in bonds.

    The legislation, known as Senate Bill 607, would first need to pass the state Legislature before giving voters the final say on the November ballot in 2026.

    “In communities across California, families are counting on science to deliver cures, protect our health, and prepare us for the challenges of the future,” said Assemblymember José Luis Solache, D-Lynwood. “Donald Trump’s cuts threaten not just research, but the lives of our loved ones. This measure makes clear that Californians will take control of our future and invest in life-saving research – because our families, our health, and our economy are too important to leave in the hands of Washington politicians playing games with people’s lives.”

    “Democrat-run states that pushed unscientific school lockdowns, toddler mask mandates, and draconian vaccine passports during the COVID era completely eroded the American people’s trust in public health agencies,” a statement from the U.S. Department of Health and Human Services read. “ACIP remains the scientific body guiding immunization recommendations in this country, and HHS will ensure policy is based on rigorous evidence and Gold Standard Science, not the failed politics of the pandemic.”

    See more coverage of top California stories here | Download our app | Subscribe to our morning newsletter | Find us on YouTube here and subscribe to our channel

    Source link

  • Teen’s medical invention saves lives in seconds

    NEWYou can now listen to Fox News articles!

    What if stopping life-threatening bleeding could be as simple as injecting a gel? That’s the promise of TRAUMAGEL, a groundbreaking, plant-based bleeding control gel now being used by first responders across the country, including a metro Atlanta fire department that recently used it to save one of their own. 

    Developed by Cresilon CEO and co-founder Joe Landolina, TRAUMAGEL works in seconds to control bleeding from gunshot wounds and other traumatic injuries. It’s supplied in a compact 30-ml syringe and can be quickly applied in the field before a patient bleeds out, a risk responsible for more than 35% of all prehospital deaths.

    STANFORD RESEARCHERS DEVELOP ‘GAME-CHANGING’ STROKE TREATMENT THAT DOUBLES EFFECTIVENESS

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide — free when you join my CyberGuy.com/Newsletter 

    A TRAUMAGEL GEL syringe sits in front of its package. (Cresilon)

    A medical breakthrough born in a winery lab

    The story behind TRAUMAGEL starts with a teenager in a winery lab. Joe Landolina, now CEO of Cresilon, developed the technology when he was just 17.

    “My grandfather was a retired chemist who owned a vineyard in upstate New York,” Landolina explains. “I would work alongside him in his winery laboratory every single day after school from a very young age. During that time, I developed a strong love for chemistry, especially plant-based chemistries from ingredients found in nature around me.”

    That love turned into research. “At the age of 17, I was experimenting with polymers extracted from the cell walls of algae and discovered a matrix that would instantly bond to living tissue,” he said.

    He took the idea to New York University’s business plan competition, and Cresilon was born. The company now operates out of a 55,000-square-foot biomanufacturing facility in Brooklyn with nearly 100 employees.

    TRAUMAGEL is a plant-based bleeding control gel.

    TRAUMAGEL works in seconds to control bleeding from severe injuries. (Cresilon)

    Real-world impact: Faster bleeding control in the field

    TRAUMAGEL is already changing how medics respond in high-pressure trauma situations.

    “TRAUMAGEL has impacted how we respond to traumatic injuries in any situation,” says Lt. David Kleiman of Cobb County Fire & Emergency Services. “In the past, with junctional injuries, like the neck, armpit, or groin, we were using traditional methods like digital pressure or wound packing. That required multiple crews and took time.

    “With TRAUMAGEL, we can administer a hemostatic agent that controls bleeding in seconds,” he continues. “Crews can move on to quicker assessments and treatments and get the patient to definitive care faster.”

    MAN’S DEADLY BRAIN CANCER TUMOR DISAPPEARS AFTER EXPERIMENTAL DRUG TRIAL

    How it saved a firefighter’s life

    In one recent case, a Cobb County firefighter was injured during a response at an abandoned house. He tripped on a hill, cut his hand on broken glass, and attempted to stop the bleeding himself. But it didn’t work.

    “He eventually realized he couldn’t control the bleeding and made his way back to the engine,” Kleiman recalls. “The crew noted that he was pale and sweaty and that his turnout gear was saturated in blood. Traditional methods failed, so they administered TRAUMAGEL. It instantly stopped the bleeding.”

    The firefighter was then treated for blood loss and fully recovered after surgery. 

    Joe Landolina, CEO of Cresilon, and his team are seen with Cobb County Fire & Emergency Services personnel.

    Cresilon CEO and co-founder Joe Landolina (center) and his team stand with Cobb County Fire & Emergency Services. (Cresilon)

    From fire departments to the Department of Defense

    Cresilon’s bleeding control gel is being tested in even more demanding environments.

    “In addition to getting TRAUMAGEL into the hands of all first responders across the country,” Landolina says, “our proprietary technology is being studied for broader applications by the U.S. Defense Department’s Walter Reed Army Institute of Research.”

    That study is focused on penetrating traumatic brain injuries (TBI). “Preliminary findings demonstrated promising results in the ability of our technology to control bleeding and provide neuroprotection following a TBI,” he says. The team plans to pursue further research based on those results. 

    What this means for you

    Severe bleeding is the number one cause of preventable death from trauma. With TRAUMAGEL, emergency teams can control that bleeding quickly, even before a patient reaches the hospital. This tool isn’t just for battlefield medicine or professional EMS. In the future, you could see it in hospitals, dental offices, and even home first-aid kits. TRAUMAGEL may become a new standard in emergency bleeding control, and that means faster care, better outcomes, and more lives saved.

    Take my quiz: How safe is your online security?

    Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you’ll get a personalized breakdown of what you’re doing right — and what needs improvement. Take my Quiz here: CyberGuy.com/Quiz

    CLICK HERE TO GET THE FOX NEWS APP

    Kurt’s key takeaways

    From a teenager’s lab experiment to a life-saving tool trusted by fire departments, TRAUMAGEL is reshaping trauma response. It’s fast, effective, and easy to use, exactly what first responders need when time is running out. As more ambulances, hospitals, and emergency personnel adopt the gel, its potential in saving lives continues to grow.

    Should every fire department in the U.S. carry this gel? Would you want TRAUMAGEL in your home first-aid kit? Let us know by writing to us at CyberGuy.com/Contact

    Sign up for my FREE CyberGuy Report
    Get my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide — free when you join my CyberGuy.com/Newsletter

    Copyright 2025 CyberGuy.com. All rights reserved.  

    Source link

  • Trump admin settles lawsuit, agrees to restore deleted DEI, gender health web pages

    NEWYou can now listen to Fox News articles!

    A large Washington-based medical association announced Tuesday they had reached a settlement with the Trump administration requiring the restoration of dozens of public health web pages and datasets tied to diversity, equity and inclusion (DEI) and gender identity.

    The Department of Health and Human Services (HHS) did not comment on the settlement, but told Fox News Digital it remains “committed to its mission of removing radical gender and DEI ideology from federal programs, subject to applicable law, to ensure taxpayer dollars deliver meaningful results for the American people.”

    The Washington State Medical Association and Doctors for America sued HHS and other agencies in May after the Trump administration, following executive orders in January, directed the removal of hundreds of web pages and datasets that referenced gender identity or diversity, equity and inclusion, LGBTQ+ health, racism, vaccines, opioid use, and Biden-era abortion policies on federal health websites.

    TRUMP ADMINISTRATION WINS SUPREME COURT FIGHT TO SLASH NIH MEDICAL RESEARCH GRANTS TIED TO DEI, LGBTQ STUDIES

    Medical groups sued the Trump administration in May after hundreds of web pages were removed following Trump’s executive orders. (Getty Images)

    The settlement requires the Trump administration to restore the deleted health web pages, though officials have not said when they will go back online. Once reposted, the guidance will again be available to doctors and patients as the president continues his push to terminate federal DEI programs.

    As of Tuesday, the medical association said the defendants “have agreed to restore webpages and data that were wrongfully deleted, ensuring that these critical resources are once again available to physicians, scientists, medical professionals, and the American public.”

    “I am extremely proud of the health care community in Washington state and our partners in this case for pushing back on this egregious example of government overreach,” Dr. John Bramhall, president of the WSMA, said in a statement. 

    In February, Bush-appointed U.S. District Judge John Bates issued a temporary restraining order requiring the content be restored while the case proceeded. The parties later agreed to pause the case in August while negotiating a resolution, leading to this week’s announced settlement.

    BIDEN-APPOINTED JUDGE HALTS TRUMP HHS OVERHAUL AFTER DEMOCRAT-LED LAWSUIT

    President Donald Trump signs the order surrounded by female athletes

    President Donald Trump, joined by female athletes, signed the “No Men in Women’s Sports” executive order in the East Room at the White House on Feb. 5, 2025 in Washington, DC. (Andrew Harnik/Getty Images)

    Court records filed Aug. 15 show both sides told the judge they had reached a settlement “in principle” and asked for a 45-day pause to finalize the deal. Biden-appointed U.S. District Judge Lauren King granted the request, formally putting the case on hold while the agreement is implemented.

    Defendants in the lawsuit include HHS Secretary Robert F. Kennedy Jr., Centers for Disease Control and Prevention (CDC) Acting Director Matthew Buzzelli, the National Institutes of Health (NIH) Director Jay Bhattacharya, the Food and Drug Administration (FDA) Commissioner Martin A. Makary, and Health Resources and Services Administration (HRSA) Administrator Thomas J. Engels. 

    Web pages from the FDA, NIH, HRSA, Department of Justice (DOJ) and Department of Veterans Affairs (VA) were also removed, according to the medical group’s complaint.

    Among the removals included the CDC’s page on supporting LGBTQ+ youth and another with facts about LGBT youth suicide. The NIH took down its Sexual & Gender Minority Research Office site, while the HHS erased an entire web page on abortion-related resources. The VA also removed a page offering guidance on medical care for LGBTQ+ veterans.

    REAGAN-NOMINATED FEDERAL JUDGE ACCUSES TRUMP ADMIN OF ‘DISCRIMINATION’ WITH CUTS TO NIH DIVERSITY GRANTS

    HHS Secretary RFK, Jr. in the Oval Office during a confirmation hearing for Dr. Mehmet Oz.

    Health and Human Services Secretary Robert F. Kennedy Jr. is one of the defendants in the medical web page lawsuit against the Trump administration. (Andrew Harnik/Getty Images)

    The Washington State Medical Association represents more than 13,000 health officials and medical students across all specialties in Washington state, according to its website.

    CLICK HERE TO GET THE FOX NEWS APP

    In January, the Trump administration began purging web pages not aligned with the president’s executive orders titled, “Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government” and “Ending Radical and Wasteful Government DEI Programs and Preferencing.” The orders directed federal agencies to recognize sex as only male and female and terminated DEI initiatives.

    Source link

  • Halsey bids big and Colman Domingo hosts Venice amfAR gala

    VENICE — Singer Halsey bid for the top lot at the amfAR Venezia fundraiser Sunday and spoke on the red carpet about how the charitable foundation’s work has helped her personally.

    Hosted by an impassioned Colman Domingo in a bright green custom Valentino jacket, the event took place at the Arsenale during the Venice Film Festival.

    More low key and intimate than it’s Cannes Film Festival counterpart, the event still attracted its share of celebrities including Jude Law, in Venice to promote “The Wizard of the Kremlin,” in which he stars as Putin.

    The evening started with champagne, canapés, Italian spritz and negronis on the waterfront terrace as a DJ spun tunes and guests viewed the artwork to be auctioned off later in the evening.

    As those attending were seated for a traditional Venetian dinner of Ombrina fish, Paris Jackson performed an acoustic set on stage.

    During the dinner there was a live auction of contemporary artworks, jewellery and destination vacations raising $3.4 million.

    Director Julian Schnabel, who will present his latest film “In the Hand of Dante” at the festival next week, donated one of his sought-after plate portraits (a portrait of the winning bidder painted on broken dishes.) Introduced on stage by Jude Law, he decided on the spot to offer up two portraits to the two highest bidders raising 500,000 euros ($586,000) for each, one of which went to singer Halsey.

    Talking earlier on the red-carpet Halsey revealed how amfAR had helped her in a very personal way:

    “I, a couple years ago got diagnosed with two pretty severe autoimmune diseases and amfAR also contributes to autoimmune and cancer research. So the work they do allows people like me with less access than me to get treatment that they really, really need to live the lives that they deserve to live. So, it’s never been closer to home that it is right now.”

    Schnabel was also presented with an Award of Inspiration from the charity in recognition of his longstanding commitment to amfAR’s lifesaving research.

    The night ended with a high octane performance from pop star Ava Max, who got everyone on their feet dancing and then it was a rush to a sea of water taxis, waiting to whisk the guests off back to their Venice hotels or on to the after-party.

    amfAR, The Foundation for AIDS Research, is a nonprofit organization dedicated to the support of AIDS research, HIV prevention, treatment education, and advocacy. Since 1985, amfAR has raised nearly $950 million in support of its programs.

    Source link

  • CDC Director Susan Monarez refuses to be fired as other officials call it quits

    NEWYou can now listen to Fox News articles!

    Longtime government scientist Susan Monarez is refusing to leave her position as director of the Centers for Disease Control and Prevention (CDC) after the Department of Health and Human Services (HHS) announced she had been removed from the role less than a month after she was sworn in.

    Attorneys Mark Zaid and Abbe Lowell said they are representing Monarez and claimed she “has neither resigned nor yet been fired.”

    The attorneys released a statement on social media, claiming HHS and Secretary Robert F. Kennedy Jr. are weaponizing public health for political gain and putting millions of American lives at risk. 

    “When CDC Director Susan Monarez refused to rubber-stamp unscientific, reckless directives and fire dedicated health experts she chose protecting the public over serving a political agenda,” the statement said. “For that, she has been targeted. Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign.”

    ABOUT 600 CDC WORKERS TERMINATED AFTER COURT CLEARS PART OF TRUMP ADMIN RESTRUCTURING PLAN

    Susan Monarez is seen here testifying during her June confirmation hearing in front of the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025. (Kayla Bartkowski/Getty Images)

    The Washington Post reported that sources within the CDC, who spoke on the condition of anonymity, said HHS leaders, including Kennedy, sought to get Monarez to commit to rescinding approvals for certain COVID-19 vaccines. When Monarez did not immediately commit, she was told by administration officials that she either needed to resign or be fired. 

    Sources also claimed that she then attempted to involve chairman of the Senate’s top health committee, Sen. Bill Cassidy, R-La. The move reportedly further angered Kennedy. 

    When reached for comment, a spokesperson for the HHS directed Fox News Digital to the agency’s response shared on its official X account.

    “Susan Monarez is no longer director of the Centers for Disease Control and Prevention,” HHS said. “We thank her for her dedicated service to the American people. Secretary Kennedy has full confidence in his team at the CDC who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad.”

    The White House did not respond to Fox News Digital’s inquiries about the matter.

    Monarez was tapped by the Trump administration to lead the CDC after its initial nominee, Dave Weldon, was withdrawn from contention in March, amid fears he might not garner enough support in the Senate to be confirmed. Shortly after Weldon stepped down, Monarez was formally nominated to be the CDC’s permanent director and was eventually confirmed in the final week of July.

    During Monarez’s confirmation, she expressed support for vaccines and told lawmakers she has “not seen a causal link between vaccines and autism.”

    MEDICAL GROUP GOES AGAINST CDC, RECOMMENDS COVID SHOTS FOR YOUNG KIDS 

    CDC logo behind syringe and vial with label that reads, Vaccine COVID-19

    In this photo illustration a syringe and an illustrative vial with COVID-19 coronavirus vaccine seen in front of the Centers for Disease Control and Prevention (CDC) logo. ( Pavlo Conchar/SOPA Images/LightRocket via Getty Images)

    Prior to Monarez’s Senate confirmation, CDC directors did not typically require Senate approval, but that changed in 2022 when Congress passed a law making it necessary. Monarez was the first-ever Senate-confirmed CDC director in the agency’s history.

    Monarez was also the first CDC director without a medical degree in more than seven decades. However, she does hold a PhD in microbiology and immunology.

    After getting her doctorate, Monarez entered the federal government, where she found herself in roles at the White House’s Office of Science and Technology Policy, the National Security Council, the Department of Homeland Security and the Advanced Research Projects Agency for Health (ARPA-H). Her bio on the CDC’s website states that she worked on “leading efforts to enhance the nation’s biomedical innovation capabilities, including combating antimicrobial resistance, expanding the use of wearables to promote patient health, ensuring personal health data privacy, and improving pandemic preparedness.”

    CLICK HERE TO GET THE FOX NEWS APP

    Trump/Monarez split

    President Donald Trump (left) nominated Susan Monarez (right) to lead the CDC. She was subsequently confirmed the last week of July, before being ousted this week, less than a month later. (Getty Images; U.S. Centers for Disease Control and Prevention)

    Hours after the news that Monarez would no longer head the CDC, sources confirmed to Fox News Digital that at least three other top CDC officials tendered their resignations, including the CDC’s director of its National Center for Immunization and Respiratory Diseases, Demetre Daskalakis, the director of the National Centers for Emerging and Zoonotic Infectious Disease, Dr. Daniel Jernigan, and the CDC’s chief medical officer, Debra Houry. 

    Resignation letters coming out from these officials have reportedly cited the Trump administration’s approach to vaccines, as well as the administration’s budget cuts.

    Fox News’ David Lewkowict contributed to this report.

    Source link

  • Supreme Court OKs Trump’s cuts to research funding

    BOSTON — Massachusetts leaders are blasting a U.S. Supreme Court court ruling that will allow the Trump administration to claw back nearly $800 million in federal grants for medical and scientific research, saying the move will hurt patients and institutions who rely on the money for lifesaving work.

    A divided Supreme Court on Thursday issued an unsigned order allowing the National Institutes of Health, the largest public funding source for biomedical research in the world, to terminate federal grants linked to diversity, equity and inclusion initiatives.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm%96 dc CF=:?8 3J E96 4@FCE’D 4@?D6CG2E:G6 >2;@C:EJ @G6CEFC?65 2 yF?6 564:D:@? 3J &]$] s:DEC:4E r@FCE ;F586 (:==:2> *@F?8 😕 q@DE@? E92E 3=@4<65 E96 42?46==2E:@? @7 E96 8C2?ED 7@C 5:G6CD:EJ :?:E:2E:G6D 2D “G@:5 2?5 :==682=” 3642FD6 E96 492?86D H6C6 32D65 @? 5:D4C:>:?2E:@? 282:?DE C24:2= >:?@C:E:6D 2?5 E96 {vq%”Z 4@>>F?:EJ]k^Am

    By Christian M. Wade | Statehouse Reporter

    Source link

  • FACT FOCUS: RFK Jr.’s reasons for cutting mRNA vaccine not supported by evidence

    Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service’s recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology.

    The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes.

    COVID-19 is the only virus for which real-world data on mRNA vaccine effectiveness is currently available, as mRNA vaccines for other diseases, including the flu, are still under development. The two scientists whose discoveries enabled the creation of mRNA vaccines against COVID-19 won a Nobel Prize in 2023 for their work.

    Kennedy’s claim ignores how mRNA vaccines work, according to experts. They prevent against severe infection and death, but cannot completely prevent an infection from occurring in the first place. Plus, years of research supports the effectiveness of COVID-19 vaccines that use mRNA technology.

    Here’s a closer look at the facts.

    KENNEDY: “As the pandemic showed us, mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract.”

    THE FACTS: His claim is contradicted by scientific evidence. Countless studies show that vaccinated individuals fare far better against COVID-19 infections than those who are unvaccinated, while others have estimated that COVID-19 vaccines prevented millions of deaths during the global pandemic. The mRNA vaccines do not prevent respiratory diseases entirely, experts say. Rather, they can prevent more serious illness that leads to complications and death. For example, an mRNA vaccine against COVID-19 may prevent an infection in the upper respiratory tract that feels like a bad cold from spreading to the lower respiratory tract, where it could affect one’s ability to breathe.

    “A vaccine cannot block a respiratory infection,” said Dr. Jake Scott, an infectious diseases physician and clinical associate professor at Stanford University School of Medicine. “That’s never been the standard for a respiratory virus vaccine. And it’s never been the expectation, and it’s never been that realistic.” He called Kennedy’s claim “misguided.”

    Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, had a similar outlook.

    “Vaccinations don’t have to be neutralizing, meaning that you’re not going to get COVID,” he said. “But the important part of a vaccination is that they reduce hospitalization and death. And a reduction in hospitalization and death is proof of an effective vaccine.”

    HHS officials did not immediately respond to a request for comment.

    Vaccines have traditionally required growing viruses or pieces of viruses called proteins and then purifying them. Then a small dose of the vaccine is injected to train the body how to recognize when a real infection hits so it’s ready to fight back. But this method takes a long time. The mRNA technology speeds up the process and allows existing vaccines to be updated more quickly.

    The “m” in mRNA stands for messenger because the vaccine carries instructions for our bodies to make proteins. Scientists figured out how to harness that natural process for vaccines by making mRNA in a lab. They take a snippet of the genetic code that carries instructions for making the protein they want the vaccine to target. Injecting that snippet instructs the body to become its own mini-vaccine factory, making enough copies of the protein for the immune system to recognize and react.

    Scott explained that mRNA vaccines are not a “magic force field” that the immune system can use to block an infection, as it can’t detect whether a virus is nearby. It can only respond to a virus that has already entered the body. In the case of COVID-19, this means that the virus could cause an upper respiratory tract infection — a cold, essentially — but would be significantly less likely to cause more severe consequences elsewhere.

    Myriad studies on the effectiveness of COVID-19 vaccines have been published since they first became available in late 2020. Although protection does wane over time, they provide the strongest barrier against severe infection and death.

    For example, a 2024 study by the World Health Organization found COVID-19 vaccines reduced deaths in the WHO’s European region by at least 57%, saving more than 1.4 million lives since their introduction in December 2020.

    A 2022 study published in the journal Lancet Infectious Diseases found that nearly 20 million lives were saved by COVID-19 vaccines during their first year. Researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom. The main finding — that 19.8 million COVID-19 deaths were prevented — is based on estimates of how many more deaths than usual occurred during the time period. Using only reported COVID-19 deaths, the same model yielded 14.4 million deaths averted by vaccines.

    Another 2022 study, published in The New England Journal of Medicine, reported that two mRNA vaccines were more than 90% effective against COVID-19.

    Operation Warp Speed, the federal effort to facilitate the development and distribution of a COVID-19 vaccine, began under the first Trump administration.

    “What I don’t understand is why is President Trump is allowing RFK Jr. to undermine his legacy that led to a medical intervention that literally saved millions of lives?” Coller said. “Why is Trump allowing RFK to undermine U.S. leadership in biomedical research and drug development?”

    ___

    Find AP Fact Checks here: https://apnews.com/APFactCheck.

    Source link

  • Alpha Genesis Proposes Innovative Management Model to Transform National Primate Research Centers

    The plan would enhance the efficiency of taxpayer-funded biomedical research amid government restructuring.

    Alpha Genesis, a premier provider of primate research models and a leader in ethical biomedical research, has announced its readiness to manage and optimize the operations of National Primate Research Centers (NPRCs) across the United States. With its expertise in efficient facility management, cutting-edge scientific research, and industry-leading animal welfare practices, Alpha Genesis aims to enhance the performance of these vital research institutions while ensuring long-term financial sustainability.

    By leveraging its operational efficiency and private-sector expertise, Alpha Genesis believes it can improve research output, streamline administrative processes, and turn NPRCs into financially viable entities without compromising their critical role in advancing medical science.

    A Vision for Sustainable and Profitable Primate Research

    The current NPRC model, funded primarily by federal grants, often faces financial strain, bureaucratic inefficiencies, and administrative hurdles that hinder scientific progress. Alpha Genesis proposes a public-private partnership model that would:

    • Increase Research Productivity: By implementing advanced management techniques and streamlining operations, Alpha Genesis would enhance the research capabilities of NPRCs, ensuring more discoveries in fields such as infectious diseases, neuroscience, and vaccine development.

    • Ensure Long-Term Financial Stability: Through strategic business management and diversified funding sources, Alpha Genesis would transition NPRCs into self-sustaining operations while maintaining their scientific integrity.

    • Enhance Animal Welfare Standards: With a proven track record in primate care, Alpha Genesis would implement the latest advancements in enrichment, housing, and veterinary care to ensure the highest ethical standards.

    • Reduce Administrative Burdens: By introducing private-sector efficiency, Alpha Genesis would cut excessive costs and allow researchers to focus on groundbreaking studies rather than bureaucratic challenges.

    “Alpha Genesis has the experience, expertise, and vision to modernize the way National Primate Research Centers operate,” said Dr. Greg Westergaard, CEO at Alpha Genesis. “By applying a business-minded approach while maintaining a strong commitment to animal welfare and scientific integrity, we can ensure that these research centers continue to drive medical breakthroughs without the financial instability they currently face.”

    A Call for Collaboration

    Alpha Genesis invites discussions with federal agencies, policymakers, and research institutions to explore this transformative approach to managing NPRCs. The organization is confident that by integrating best practices from both the private and public sectors, it can create a more effective and sustainable research ecosystem that benefits both science and society.

    For more information about Alpha Genesis and its vision for the future of primate research, please visit www.alphagenesisinc.com or contact info@alphagenesisinc.com / 843-589-5190.

    Contact Information

    Dr. Greg Westergaard
    President and CEO
    gwprimate@alphagenesisinc.com
    843-589-5190

    Source: Alpha Genesis, Inc.

    Source link

  • Medicare Advantage shopping season arrives with a dose of confusion and some political implications

    Medicare Advantage shopping season arrives with a dose of confusion and some political implications

    Thinner benefits and coverage changes await many older Americans shopping for health insurance this fall. That’s if their plan is even still available in 2025.

    More than a million people will probably have to find new coverage as major insurers cut costs and pull back from markets for Medicare Advantage plans, the privately run version of the federal government’s coverage program mostly for people ages 65 and older.

    Industry experts also predict some price increases for Medicare prescription drug plans as required coverage improvements kick in.

    Voters will learn about the insurance changes just weeks before they pick the next president and as Democrat Kamala Harris campaigns on promises to lower health care costs. Early voting has already started in some states.

    “This could be bad news for Vice President Harris. If that premium is going up, that’s a very obvious sign that you’re paying more,” said Massey Whorley, an analyst for health care consulting company Avalere. “That has significant implications for how they’re viewing the performance of the current administration.”

    Insurance agents say the distraction of the election adds another complication to an already challenging annual enrollment window that starts next month.

    Insurers are pulling back from Medicare Advantage

    Medicare Advantage plans will cover more than 35 million people next year, or around half of all people enrolled in Medicare, according to the federal government. Insurance agents say they expect more people than usual will have to find new coverage for 2025 because their insurer has either ended a plan or left their market.

    The health insurer Humana expects more than half a million customers — about 10% of its total — to be affected as it pulls Medicare Advantage plans from places around the country. Many customers will be able to transfer to other Humana plans, but company leaders still anticipate losing a few hundred thousand customers.

    CVS Health’s Aetna projects a similar loss, and other big insurers have said they are leaving several states.

    Insurers say rising costs and care use, along with reimbursement cuts from the government, are forcing them to pull back.

    Some people can expect a tough search

    When insurers leave Medicare Advantage markets, they tend to stop selling plans that have lower quality ratings and those with a higher proportion of Black buyers, said Dr. Amal Trivedi, a Brown University public health researcher.

    He noted that market exits can be particularly hard on people with several doctors and on patients with cognitive trouble like dementia.

    Most markets will still have dozens of plan choices. But finding a new option involves understanding out-of-pocket costs for each choice, plus figuring out how physicians and regular prescriptions are covered.

    “People don’t like change when it comes to health insurance because you don’t know what’s on the other side of the fence,” said Tricia Neuman, a Medicare expert at KFF, a nonprofit that researches health care.

    Plans that don’t leave markets may raise deductibles and trim perks like cards used to pay for utilities or food.

    Those proved popular in recent years as inflation rose, said Danielle Roberts, co-founder of the Fort Worth, Texas, insurance agency Boomer Benefits.

    “It’s really difficult for a person on a fixed income to choose a health plan for the right reasons … when $900 on a flex card in free groceries sounds pretty good,” she said.

    Don’t “sleep” on picking a Medicare plan

    Prices also could rise for some so-called standalone Part D prescription drug plans, which people pair with traditional Medicare coverage. KFF says that population includes more than 13 million people.

    The Centers for Medicare and Medicaid Services said Friday that premiums for these plans will decrease about 4% on average to $40 next year.

    But brokers and agents say premiums can vary widely, and they still expect some increases. They also expect fewer plan choices and changes to formularies, or lists of covered drugs. Roberts said she has already seen premium hikes of $30 or more from some plans for next year.

    Any price shift will hit a customer base known to switch plans for premium changes as small as $1, said Fran Soistman, CEO of the online insurance marketplace eHealth.

    The changes come as a congressional-approved coverage overhaul takes hold. Most notably, out-of-pocket drug costs will be capped at $2,000 for those on Medicare, an effort championed by Democrats and President Joe Biden in 2022.

    In the long run, these changes will lead to a “much richer benefit,” Whorley said.

    KFF’s Neuman noted that the cap on drug costs will be especially helpful to cancer patients and others with expensive prescriptions. She estimates about 1.5 million people will benefit.

    To ward off big premium spikes because of the changes, the Biden administration will pull billions of dollars from the Medicare trust fund to pay insurers to keep premium prices down, a move some Republicans have criticized. Insurers will not be allowed to raise premium prices beyond $35 next year.

    People will be able to sign up for 2025 coverage between Oct. 15 and Dec. 7. Experts say all the potential changes make it important for shoppers to study closely any new choices or coverage they expect to renew.

    “This is not a year to sleep on it, just re-enroll in the status quo,” said Whorley, the health care analyst.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    Source link

  • WNBA star Breanna Stewart raises awareness for marrow donor program after death of father-in-law

    WNBA star Breanna Stewart raises awareness for marrow donor program after death of father-in-law

    NEW YORK — Breanna Stewart lost her father-in-law, Josep Xargay, to cancer nearly a year ago.

    Stewart is now helping raise awareness for the disease, joining the national marrow donor program.

    “It was pretty deep,” Stewart said in an interview with the AP, pausing for a moment to regain her composure, about her loss. “I don’t think it ever got to the point where he could get on a transplant list or anything. I don’t know if I’ll be able to donate at some point, but just doing what I can to help spread the word.”

    Stewart took part Saturday in an event in New York called NMDP Unite, which falls on the global celebration of World Marrow Donor Day. The event helped raise funds for NMDP’s patient assistance program and blood stem cell research initiatives.

    She shook hands and posed for photos with the attendees and also took a swab to join the NMDP registry.

    The Liberty star also recently met after a game with Brian Kevan, a New York firefighter who was at 9/11. Kevan had cancer and now is free of it thanks to a blood stem cell donation he received. The pair reconnected on Saturday at the event.

    “It’s really inspirational and something I wanted to be a part of,” Stewart said. “He was a firefighter in 9/11, which is even more inspiring and incredible.”

    Stewart said she was only seven years old on Sept. 11, but remembers vividly the emotions of the day.

    “We were in school and we were supposed to watch something on TV that day, and all of a sudden, like, the teachers were just getting, like, really emotional.,” she recalled. “We couldn’t watch anything. We got sent home early, and I came home and my mom was on her on the couch crying, watching the news.”

    Stewart also met that night after the Liberty game another cancer patient who attended UConn with her. That patient hasn’t required a transplant yet.

    “Hopefully I can inspire them as they’re inspiring me and, you know, when you get this opportunity to meet people who are really fighting for their lives, it puts life into perspective,” Stewart said.

    The Liberty forward said with the anniversary of her father-in-law’s death coming up it will be hard on their family.

    “I’ll continue to get through it by helping others and this was one way,” she said.

    ___

    AP WNBA: https://apnews.com/hub/wnba-basketball

    Source link